Erratum: Scleroderma renal crisis and renal involvement in systemic sclerosis (Nature Reviews Nephrology (2016) 12 (678-691) DOI: 10.1038/nrneph.2016.124);Scleroderma renal crisis and renal involvement in systemic sclerosis

Nature Reviews Nephrology

Volumn 12, Issue 11, 2016, Pages 678-691

  Woodworth, Thasia G ^a   Suliman, Yossra A ^a,b   Furst, Daniel E ^a   Clements, Philip ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ASSIUT UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN 1 RECEPTOR ANTAGONIST; ENDOTHELIN RECEPTOR ANTAGONIST; IMMUNOSUPPRESSIVE AGENT; UNCLASSIFIED DRUG;

ANCA ASSOCIATED VASCULITIS; CHRONIC KIDNEY FAILURE; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; INCIDENCE; KIDNEY DISEASE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; KIDNEY VASCULAR RESISTANCE; OUTCOME ASSESSMENT; PATHOLOGY; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS; RECURRENT DISEASE; RENAL FUNCTIONAL RESERVE; RENAL SYSTEM PARAMETERS; REVIEW; RISK FACTOR; SCLERODERMA RENAL CRISIS; SYSTEMIC SCLEROSIS; COMPLICATION; HYPERTENSION, RENAL; KIDNEY DISEASES;

HUMANS; HYPERTENSION, RENAL; KIDNEY DISEASES; SCLERODERMA, SYSTEMIC;

EID: 84988372364     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2017.183     Document Type: Erratum

References (100)

1. Mayes, M. D., et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum. 48, 2246-2255 (2003).
2. Chifflot, H., Fautrel, B., Sordet, C., Chatelus, E., & Sibilia, J. Incidence and prevalence of systemic sclerosis: a systematic literature review. Semin. Arthritis Rheum. 37, 223-235 (2008).
3. Barnes, J., & Mayes, M. D. Epidemiology of systemic sclerosis: incidence, prevalence, survival, risk factors, malignancy, and environmental triggers. Curr. Opin. Rheumatol. 24, 165-170 (2012).
4. Steen, V. D., Syzd, A., Johnson, J. P., Greenberg, A., & Medsger, T. A. Jr. Kidney disease other than renal crisis in patients with diffuse scleroderma. J. Rheumatol. 32, 649-655 (2005).
5. Denton, C. P. Renal manifestations of systemic sclerosis-clinical features and outcome assessment. Rheumatology 47 (Suppl. 5), v54-v56 (2008).
6. Clements, P. J., et al. Abnormalities of renal physiology in systemic sclerosis. A prospective study with 10 year followup. Arthritis Rheum. 37, 67-74 (1994).
7. Caron, M., et al. Longitudinal study of renal function in systemic sclerosis. J. Rheumatol. 39, 1829-1834 (2012).
8. DeMarco, P. J., et al. Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D penicillamine in early diffuse systemic sclerosis trial. Arthritis Rheum. 46, 2983-2989 (2002).
9. Hudson, M., et al. Exposure to ACE inhibitors prior to the onset of scleroderma renal crisis-results from the International Scleroderma Renal Crisis Survey. Semin. Arthritis Rheum. 43, 666-672 (2014).
10. Denton, C. P., Lapadula, G., Mouthon, L., & Muller-Ladner, U. Renal complications and scleroderma renal crisis. Rheumatology 48 (Suppl. 3), iii32-iii35 (2009).
11. Steen, V. D., et al. Factors predicting development of renal involvement in progressive systemic sclerosis. Am. J. Med. 76, 779-786 (1984).
12. Avouac, J., et al. Joint and tendon involvement predict disease progression in systemic sclerosis: a EUSTAR prospective study. Ann. Rheum. Dis. 75, 103-109 (2016).
13. Teixeira, L., et al. Mortality and risk factors of scleroderma renal crisis: a French retrospective study of 50 patients. Ann. Rheum. Dis. 67, 110-116 (2008).
14. Penn, H., et al. Scleroderma renal crisis: patient characteristics and long-Term outcomes. Q. J. Med. 100, 485-494 (2007).
15. Kingdon, E. J., et al. Calculated glomerular filtration rate is a useful screening tool to identify scleroderma patients with renal impairment. Rheumatology 42, 26-33 (2003).
16. Scheja, A., Bartosik, I., Wuttge, D. M., & Hesselstrand, R. Renal function is mostly preserved in patients with systemic sclerosis. Scand. J. Rheumatol. 38, 295-298 (2009).
17. Mohamed, R. H., Zayed, H. S., & Amin, A. Renal disease in systemic sclerosis with normal serum creatinine. Clin. Rheumatol. 29, 729-737 (2010).
18. Campo, A., et al. Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 182, 252-260 (2010).
19. Bosch, J. P., et al. Renal functional reserve in humans. Effect of protein intake on glomerular filtration rate. Am. J. Med. 75, 943-950 (1983).
20. Livi, R., et al. Renal functional reserve is impaired in patients with systemic sclerosis without clinical signs of kidney involvement. Ann. Rheum. Dis. 61, 682-686 (2002).
21. Livi, R., et al. Lack of activation of renal functional reserve predicts the risk of significant renal involvement in systemic sclerosis. Ann. Rheum. Dis. 70, 1963-1967 (2011).
22. Amin, A., El Sayed, S., Taher, N., Sedki, M., & Nasr, H. Tc 99m diethylenetriamine pentaacetic acid (DTPA) renal function reserve estimation: is it a reliable predictive tool for assessment of preclinical renal involvement in scleroderma patients?. Clin. Rheumatol. 31, 961-966 (2012).
23. Rosato, E., et al. Intrarenal hemodynamic parameters correlate with glomerular filtration rate and digital microvascular damage in patients with systemic sclerosis. Semin. Arthritis Rheum. 41, 815-821 (2012).
24. Granata, A., et al. Resistive intrarenal index: myth or reality?. Br. J. Radiol. 87, 20140004 (2014).
25. Rivolta, R., et al. Renal vascular damage in systemic sclerosis patients without clinical evidence of nephropathy. Arthritis Rheum. 39, 1030-1034 (1996).
26. Scorza, R., et al. Effect of iloprost infusion on the resistance index of renal vessels of patients with systemic sclerosis. J. Rheumatol. 24, 1944-1948 (1997).
27. Shanmugam, V. K., & Steen, V. D. Renal manifestations in scleroderma: evidence for subclinical renal disease as a marker of vasculopathy. Int. J. Rheumatol. 2010, 538589 (2010).
28. Anavekar, N. S., et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N. Engl. J. Med. 351, 1285-1295 (2004).
29. Klausen, K., et al. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation 110, 32-35 (2004).
30. Lambers Heerspink, H. J., et al. Albuminuria assessed from first-morning-void urine samples versus 24 hour urine collections as a predictor of cardiovascular morbidity and mortality. Am. J. Epidemiol. 168, 897-905 (2008).
31. Hillege, H. L., et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 106, 1777-1782 (2002).
32. Seiberlich, B., Hunzelmann, N., Krieg, T., Weber, M., & Schulze-Lohoff, E. Intermediate molecular weight proteinuria and albuminuria identify scleroderma patients with increased morbidity. Clin. Nephrol. 70, 110-117 (2008).
33. Bussone, G., Berezne, A., Pestre, V., Guillevin, L., & Mouthon, L. The scleroderma kidney: progress in risk factors, therapy, and prevention. Curr. Rheumatol. Rep. 13, 37-43 (2011).
34. Guillevin, L., et al. Scleroderma renal crisis: a retrospective multicentre study on 91 patients and 427 controls. Rheumatology. 51, 460-467 (2012).
35. Steen, V. D., & Medsger, T. A. Jr. Long-Term outcomes of scleroderma renal crisis. Ann. Intern. Med. 133, 600-603 (2000).
36. Steen, V. D., Costantino, J. P., Shapiro, A. P., & Medsger, T. A. Jr. Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann. Intern. Med. 113, 352-357 (1990).
37. Walker, J. G., et al. Scleroderma renal crisis: poor outcome despite aggressive antihypertensive treatment. Int. Med. J. 33, 216-220 (2003).
38. Muangchan, C., Canadian Scleroderma Research Group, Baron, M., & Pope, J. The 15% rule in scleroderma: the frequency of severe organ complications in systemic sclerosis. A systematic review. J. Rheumatol. 40, 1545-1556 (2013).
39. Maurer, B., et al. Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database. Ann. Rheum. Dis. 74, 1124-1131 (2015).
40. Varma, S., et al. Cytodiagnosis of granulocytic sarcoma presenting as superior vena cava syndrome in acute myeloblastic leukemia. A case report. Acta Cytol. 36, 371-372 (1992).
41. Glassock, R. J., & Rule, A. D. The implications of anatomical and functional changes of the aging kidney: with an emphasis on the glomeruli. Kidney Int. 82, 270-277 (2012).
42. Mouthon, L., Bussone, G., Berezne, A., Noel, L. H., & Guillevin, L. Scleroderma renal crisis. J. Rheumatol. 41, 1040-1048 (2014).
43. Batal, I., Domsic, R. T., Medsger, T. A., & Bastacky, S. Scleroderma renal crisis: a pathology perspective. Int. J. Rheumatol. 2010, 543704 (2010).
44. Shanmugam, V. K., & Steen, V. D. Renal disease in scleroderma: an update on evaluation, risk stratification, pathogenesis and management. Curr. Opin. Rheumatol. 24, 669-676 (2012).
45. Mouthon, L., et al. Endothelin 1 expression in scleroderma renal crisis. Hum. Pathol. 42, 95-102 (2011).
46. Penn, H., et al. Targeting the endothelin axis in scleroderma renal crisis: rationale and feasibility. Q. J. Med. 106, 839-848 (2013).
47. Sobanski, V., et al. Prevalence of anti-RNA polymerase III antibodies in systemic sclerosis: new data from a French cohort and a systematic review and meta-Analysis. Arthritis Rheumatol. 66, 407-417 (2014).
48. Dore, A., et al. Significance of palpable tendon friction rubs in early diffuse cutaneous systemic sclerosis. Arthritis Care Res. 65, 1385-1389 (2013).
49. Nikpour, M., et al. Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort. Arthritis Res. Ther. 13, R211 (2011).
50. Nguyen, B., Assassi, S., Arnett, F. C., & Mayes, M. D. Association of RNA polymerase III antibodies with scleroderma renal crisis. J. Rheumatol. 37, 1068-1069 (2010).
51. Fonseca, C., et al. Endothelin axis polymorphisms in patients with scleroderma. Arthritis Rheum. 54, 3034-3042 (2006).
52. Helfrich, D. J., Banner, B., Steen, V. D., & Medsger, T. A. Jr. Normotensive renal failure in systemic sclerosis. Arthritis Rheum. 32, 1128-1134 (1989).
53. Steen, V. D., & Medsger, T. A. Jr. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum. 41, 1613-1619 (1998).
54. Iudici, M., van der Goes, M. C., Valentini, G., & Bijlsma, J. W. Glucocorticoids in systemic sclerosis: weighing the benefits and risks-A systematic review. Clin. Exp. Rheumatol. 31 (Suppl. 76), 157-165 (2013).
55. Keeler, E., Fioravanti, G., Samuel, B., & Longo, S. Scleroderma renal crisis or thrombotic thrombocytopenic purpura: seeing through the masquerade. Lab Med. 46, e39-e44 (2015).
56. Arad, U., et al. Anti-neutrophil antibody associated vasculitis in systemic sclerosis. Semin. Arthritis Rheum. 41, 223-229 (2011).
57. Rho, Y. H., Choi, S. J., Lee, Y. H., Ji, J. D., & Song, G. G. Scleroderma associated with ANCA-Associated vasculitis. Rheumatol. Int. 26, 369-375 (2006).
58. Akimoto, S., Ishikawa, O., Tamura, T., & Miyachi, Y. Antineutrophil cytoplasmic autoantibodies in patients with systemic sclerosis. Br. J. Dermatol. 134, 407-410 (1996).
59. Derrett-Smith, E. C., Nihtyanova, S. I., Harvey, J., Salama, A. D., & Denton, C. P. Revisiting ANCA-Associated vasculitis in systemic sclerosis: clinical, serological and immunogenetic factors. Rheumatology 52, 1824-1831 (2013).
60. Chan, P. T., & Mok, C. C. Pauci-immune crescentic glomerulonephritis in limited cutaneous systemic sclerosis. Clin. Rheumatol. 31, 1273-1277 (2012).
61. Quemeneur, T., et al. Systemic vasculitis during the course of systemic sclerosis: report of 12 cases and review of the literature. Medicine 92, 1-9 (2013).
62. Manadan, A. M., Harris, C., & Block, J. A. Thrombotic thrombocytopenic purpura in the setting of systemic sclerosis. Semin. Arthritis Rheum. 34, 683-688 (2005).
63. Cozzi, F., et al. Prognosis of scleroderma renal crisis: a long-Term observational study. Nephrol. Dial. Transplant. 27, 4398-4403 (2012).
64. Coppo, P., & Veyradier, A. Current management and therapeutical perspectives in thrombotic thrombocytopenic purpura. Presse Med. 41, e163-e176 (2012).
65. Kao, L., & Weyand, C. Vasculitis in systemic sclerosis. Int. J. Rheumatol. 2010, 385938 (2010).
66. Giuggioli D., et al. Systemic sclerosis and cryoglobulinemia: our experience with overlapping syndrome of scleroderma and severe cryoglobulinemic vasculitis and review of the literature. Autoimmun. Rev. 12, 1058-1063 (2013).
67. Furuta, S., & Jayne, D. Emerging therapies in antineutrophil cytoplasm antibody-Associated vasculitis. Curr. Opin. Rheumatol. 26, 1-6 (2014).
68. Specks, U., et al. Efficacy of remission-induction regimens for ANCA-Associated vasculitis. N. Engl. J. Med. 369, 417-427 (2013).
69. Charles, P., et al. Rituximab: recommendations of the French Vasculitis Study Group (FVSG) for induction and maintenance treatments of adult, antineutrophil cytoplasm antibody-Associated necrotizing vasculitides. Presse Med. 42, 1317-1330 (2013).
70. Miloslavsky, E. M., et al. Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-Associated vasculitis. Arthritis Rheum. 65, 2441-2449 (2013).
71. Roll, P., et al. Efficacy and safety of rituximab treatment in patients with antineutrophil cytoplasmic antibody-Associated vasculitides: results from a German registry (GRAID). J. Rheumatol. 39, 2153-2156 (2012).
72. Gomez-Puerta, J. A., Quintana, L. F., Stone, J. H., Ramos-Casals, M., & Bosch, X. B Cell depleting agents for ANCA vasculitides: a new therapeutic approach. Autoimmun. Rev. 11, 646-652 (2012).
73. Lopez-Ovejero, J. A., et al. Reversal of vascular and renal crises of scleroderma by oral angiotensin-converting-enzyme blockade. N. Engl. J. Med. 300, 1417-1419 (1979).
74. Zawada, E. T., et al. Clinical course of patients with scleroderma renal crisis treated with captopril. Nephron 27, 74-78 (1981).
75. Traub, Y. M., et al. Hypertension and renal failure (scleroderma renal crisis) in progressive systemic sclerosis. Review of a 25 year experience with 68 cases. Medicine 62, 335-352 (1983).
76. Montanelli, G., Beretta, L., Santaniello, A., & Scorza, R. Effect of dihydropyridine calcium channel blockers and glucocorticoids on the prevention and development of scleroderma renal crisis in an Italian case series. Clin. Exp. Rheumatol. 31 (Suppl. 76), 135-139 (2013).
77. Walker, K. M., et al. Treatment of systemic sclerosis complications: what to use when first-line treatment fails-A consensus of systemic sclerosis experts. Semin. Arthritis Rheum. 42, 42-55 (2012).
78. Mann, J. F., et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 372, 547-553 (2008).
79. Pope J., et al. Prazosin for Raynaud?s phenomenon in progressive systemic sclerosis. Cochrane Database Systematic Reviews, Issue 2. Art. No.: CD000956. http://dx.doi.org/10.1002/14651858.CD000956
80. Mohokum, M., Hartmann, P., & Schlattmann, P. The association of Raynaud syndrome with beta-blockers: a meta-Analysis. Angiology 63, 535-540 (2012).
81. Avouac, J., Wipff, J., Kahan, A., & Allanore, Y. Effects of oral treatments on exercise capacity in systemic sclerosis related pulmonary arterial hypertension: a meta-Analysis of randomised controlled trials. Ann. Rheum. Dis. 67, 808-814 (2008).
82. Izzedine, H., Rouvier, P., & Deray, G. Endothelin receptor antagonism-based treatment for scleroderma renal crisis. Am. J. Kidney Dis. 62, 394-395 (2013).
83. US National Library of Medicine ClinicalTrials.gov [online] https://clinicaltrials.gov/ct2/show/NCT01241383 (2015).
84. Kohan, D. E., & Barton, M. Endothelin and endothelin antagonists in chronic kidney disease. Kidney Int. 86, 896-904 (2014).
85. Himmelfarb, J., & Tuttle, K. R. New therapies for diabetic kidney disease. N. Engl. J. Med. 369, 2549-2550 (2013).
86. Eckardt, K. U., et al. Evolving importance of kidney disease: from subspecialty to global health burden. Lancet 382, 158-169 (2013).
87. US National Library of Medicine ClinicalTrials.gov [online] https://clinicaltrials.gov/ct2/show/NCT01858532 (2016).
88. Denton, C. P., & Black, C. M. Scleroderma-clinical and pathological advances. Best Pract. Res. Clin. Rheumatol. 18, 271-290 (2004).
89. Schioppo, T., et al. N TproBNP as biomarker in systemic sclerosis. Clin. Rev. Allergy Immunol. 43, 292-301 (2012).
90. Gibney, E. M., et al. Kidney transplantation for systemic sclerosis improves survival and may modulate disease activity. Am. J. Transplant. 4, 2027-2031 (2004).
91. Siva, B., et al. End-stage kidney disease due to scleroderma-outcomes in 127 consecutive ANZDATA registry cases. Nephrol. Dial. Transplant. 26, 3165-3171 (2011).
92. Pham, P. T., et al. Predictors and risk factors for recurrent scleroderma renal crisis in the kidney allograft: case report and review of the literature. Am. J. Transplant. 5, 2565-2569 (2005).
93. Shegogue, D., & Trojanowska, M. Mammalian target of rapamycin positively regulates collagen type I production via a phosphatidylinositol 3 kinase-independent pathway. J. Biol. Chem. 279, 23166-23175 (2004).
94. Su, T. I., et al. Rapamycin versus methotrexate in early diffuse systemic sclerosis: results from a randomized, single-blind pilot study. Arthritis Rheum. 60, 3821-3830 (2009).
95. Clements, P. J., et al. Cyclosporine in systemic sclerosis. Results of a forty-eight-week open safety study in ten patients. Arthritis Rheum. 36, 75-83 (1993).
96. Chang, Y. J., & Spiera, H. Renal transplantation in scleroderma. Medicine 78, 382-385 (1999).
97. Mangray, M., & Vella, J. P. Hypertension after kidney transplant. Am. J. Kidney Dis. 57, 331-341 (2011).
98. Cheung, W. Y., Gibson, I. W., Rush, D., Jeffery, J., & Karpinski, M. Late recurrence of scleroderma renal crisis in a renal transplant recipient despite angiotensin II blockade. Am. J. Kidney Dis. 45, 930-934 (2005).
99. Hudson, M., et al. An international, web-based, prospective cohort study to determine whether the use of ACE inhibitors prior to the onset of scleroderma renal crisis is associated with worse outcomes-methodology and preliminary results. Int. J. Rheumatol. 210, 347402 (2010).
100. Hesselstrand, R., Scheja, A., & Wuttge, D. M. Scleroderma renal crisis in a Swedish systemic sclerosis cohort: survival, renal outcome, and RNA polymerase III antibodies as a risk factor. Scand. J. Rheumatol. 41, 39-43 (2012).